Dr Reddy's Lab down 5% to hit 52-week low, top Sensex loser

The stock slipped 5% to Rs 2,602 on BSE in intra-day trade on back of heavy volumes.

reddy, dr reddy's
Dr Reddy's laboratory
SI Reporter Mumbai
Last Updated : Mar 21 2017 | 11:34 AM IST

Don't want to miss the best from Business Standard?

Dr Reddy's Laboratories slipped to its 52-week low of Rs 2,602, down 5% on BSE in intra-day trade on back of heavy volumes.

The BSE said the exchange has sought clarification from Dr Reddys Laboratories on March 21, 2017, with reference to news flashed on ET Now dated March 21, 2017 quoting "US FDA finds repeat observations from 2015 warning letter. Failed to maintain complete data to ensure compliance."

The reply is awaited.

Earlier, on March 9, 2017, the stock of pharmaceutical company hit a low of Rs 2,702 after it said the US drug regulator issued a Form 483 with 13 observations for the company’s formulation manufacturing facility at Duwada, Visakhapatnam.

“The audit of Company's formulation manufacturing facilty at Duwada, Visakhapatnam, by the US FDA, has been completed on March 08, 2017. The Company has been issued a Form 483 with 13 observations, which the Company is addressing,” Dr Reddys Laboratories had said in a BSE filing.

At 10:47 am; the stock was down 4% at Rs 2,630 on BSE as compared to 0.11% decline in the S&P BSE Sensex. The trading volumes on the counter nearly doubled with a combined 858,883 shares changed hands on BSE and NSE so far.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Next Story